The global amphetamine drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Amphetamines are a type of stimulant drug that is used to treat attention deficit hyperactivity disorder (ADHD). Amphetamine is classified as a stimulant, which means it belongs to the same drug class as other stimulants. It can assist in increasing the attention span and dealing with behavioral issues. It could additionally, aid task organization and the development of listening skills. The major factors driving the growth of the amphetamine market include government programs in numerous countries to raise awareness of the ADHD illness and its treatment. Another factor driving the market growth is a growing awareness of the importance of mental health among individuals all around the globe.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Amphetamine Drug at: https://orionmarketreports.com/request-sample/?id=103645&submit=Request+Sample%0D%0A
The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, in order to stay competitive in the market. For instance-
- In December 2021, The USFDA approved Granules India Ltd. for its generic amphetamine mixed salts for the treatment of ADHD and narcolepsy. The company serves the amphetamine mixed salts in strengths of 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg, and 30mg instant release tablets.
- In November 2021, Tris Pharma, Inc. (Tris). announced that the USFDA has approved Dyanavel XR (amphetamine), extended-release once-daily tablets, CII, for the treatment of ADHD in patients of age 6 and above. In Phase-3 clinical investigation of 6 to 12-year-old children with ADHD, Dyanavel XR extended-release tablets were found to be bioequivalent to Dyanavel XR extended-release oral suspension, which showed ADHD symptom improvement within 1 hour and continued for 13 hours following once-daily treatment.
- In January 2021, The USFDA has given final approval to Glenmark Pharma’s amphetamine sulfate tablets. The medicine is a generic version of Arbor Pharmaceutical’s Evekeo tablets. Tablets containing amphetamine sulfate are used to treat ADHD and narcolepsy, a sleep disorder. It’s additionally, used as a short-term treatment for weight loss, along with a low-calorie diet and exercise.
A full report of Global Amphetamine Drug Market is available at: https://orionmarketreports.com/amphetamine-drug-market/103645/
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Drug Types
- By Distribution Channels
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
· Competitive Landscape- Eli Lily & Company, Pfizer Inc., GlaxoSmithKline plc., Johnson & Johnson Services, LLC, and Lupin Ltd., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Amphetamine Drug Market Report by Segment
By Drug Types
- Stimulant
- Non-stimulant
By Distribution Channels
- Hospitals Pharmacy
- Retail Pharmacy
- Online Pharmacy
About Us:
Orion Market Reports (OMR) endeavors to provide an exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and the most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
